leadf
logo-loader
viewSensyne Health PLC

Sensyne Health develops an app that can accurately read a lateral flow coronavirus test in less than two seconds

The group's MagnifEye technology uses a cloud-based deep learning algorithm to automate the process

Sensyne Health PLC -

Sensyne Health PLC (LON:SENS) has launched a smartphone app that can accurately read and analyse a lateral flow coronavirus (COVID-19) test in under two seconds.

The group's MagnifEye technology uses a cloud-based deep learning algorithm to automate the process. It can be quickly ‘trained’ for alternative uses such as to assess for cancer, infectious disease and fertility, as well as being deployed for plant pathogen and environmental testing. 

Marketed as a business-to-business commercial product, it exists not just as a smartphone app but can be incorporated into a website or native software applications.

As well as being fast and accurate (by avoiding human error), MagnifEye is also secure and has been set to ensure results can't be tampered with. The automated system is platform agnostic.

“Diagnostic testing has seen rapid progress over the past year, accelerated by responses to the COVID-19 pandemic,” said Sensyne chief executive, Lord Drayson in a statement.

“We have been working on developing a general capability to automate the reading of lateral flow tests in response to demand from commercial test manufacturers and healthcare providers. We look forward to working with these potential partners to apply this technology as rapidly as possible."

Quick facts: Sensyne Health PLC

Price: 144 GBX

AIM:SENS
Market: AIM
Market Cap: £229.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sensyne Health PLC named herein, including the promotion by the Company of Sensyne Health PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: The FTSE dismisses Trump's 2nd impeachment to focus on...

The Market Report with Katie Pilbeam. FTSE 100 was boosted by vaccination hopes and a deluge of company announcements with confirmation of President Trump’s second impeachment having little impact. London’s blue-chip index rose 20 to 6,766. Donald Trump has become the first US president in...

3 days, 1 hour ago

2 min read